HARMONY Partner European LeukemiaNet (ELN) is organizing a virtual meeting on March 9, 2021 to discuss the latest insights in the treatment of leukemia. In two dedicated sessions, HARMONY representatives will discuss how HARMONY is addressing important research questions in leukemia.
HARMONY Partner Rüdiger Hehlmann, Professor of Medicine and founder and chair of the European LeukemiaNet:
"HARMONY is focusing on a broad range of blood cancers, including acute and chronic leukemias, and the ELN has has joined HARMONY from the start. By assembling anonymized data sets of thousands of patients into the unique HARMONY Big Data Platform, we can characterize the molecular landscape of these diseases, understand their pathophysiology, and identify novel drug targets. In addition, it will allow us to reliably predict disease course and drug response for subgroups of patients. HARMONY’s results should ultimately provide tools for healthcare professionals to rapidly select the most promising treatment for an individual patient with leukemia."
Topics of the dedicated ELN-HARMONY/HARMONY PLUS sessions:
Click here to open the agenda/view ELN_HARMONY speakers >
Click here to open the agenda/view the ELN HARMONY PLUS speakers >
Click here for an overview of all ELN WP sessions >
Big Data accelerate better and faster treatment for Patients with Hematologic Malignancies |The HARMONY Alliance is a Public-Private Partnership [HARMONY & HARMONY PLUS] funded by Innovative Medicines Initiative. HARMONY uses big data technologies to improve the treatment of blood cancers i.e. Hematologic Malignancies. Key outstanding questions in the blood cancer field can only be answered by studying large numbers of patients. Therefore, the HARMONY Alliance developed the HARMONY Big Data Platform, assembling harmonized clinical data from approx. 60.000 European patients. This will enable HARMONY researchers to characterize the molecular landscape of the various blood cancers, understand their pathophysiology, and identify novel drug targets. In addition, it will allow to reliably predict disease course and drug response for subgroups of patients. Ultimately, this should result in tools to rapidly select the most promising treatment strategy for a particular patient. In parallel, the HARMONY Alliance is developing core outcome sets for blood cancers.
Co-operative working groups, hospitals and academic institutions are invited to collaborate and contribute data to the HARMONY Alliance.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
